Among them, Apcin and pro-TAME have been identified as selective CDC20 and APC/CCDC20/APC/CCDH1 inhibitors [152], respectively, and are currently under preclinical investigation for their efficacy against different cancer subtypes, including hematological malignancies. Here, CDC20 is linked to cancer.